secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001437749-23-023999
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva completes enrollment in Phase 3 RECOVER study for brilaroxazine in schizophrenia; topline data expected Oct 2023
--------------------------------------------------------------------------------

- Enrollment of 402 patients across US (~60%), Europe (~10%), and Asia (~30%) in pivotal Phase 3 RECOVER trial.
- Topline efficacy and safety data for RECOVER expected in October 2023.
- Over 50% of patients enrolled in 1-year open-label extension study; completion expected in Q3 2024.
- Primary endpoint: change in PANSS total score from baseline to Day 28 vs placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923023999/0001437749-23-023999-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923023999/rvph20230816_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023999

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer